SG11201507334VA - Methods of using zscan4 for rejuvenating human cells - Google Patents

Methods of using zscan4 for rejuvenating human cells

Info

Publication number: SG11201507334VA
Authority: SG; Singapore
Prior art keywords: zscan4; methods; human cells; rejuvenating human; rejuvenating
Prior art date: 2013-03-15

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-03-14Application filed by Elixirgen LlcfiledCriticalElixirgen Llc

2015-10-29Publication of SG11201507334VApublicationCriticalpatent/SG11201507334VA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/33—Fibroblasts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0608—Germ cells
- C12N5/0609—Oocytes, oogonia
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/04—Immortalised cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18811—Sendai virus
- C12N2760/18841—Use of virus, viral particle or viral elements as a vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18811—Sendai virus
- C12N2760/18841—Use of virus, viral particle or viral elements as a vector
- C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
Immunology (AREA)
General Engineering & Computer Science (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Biophysics (AREA)
Developmental Biology & Embryology (AREA)
Physics & Mathematics (AREA)
Cell Biology (AREA)
Neurology (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Analytical Chemistry (AREA)
Plant Pathology (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)

SG11201507334VA2013-03-152014-03-14Methods of using zscan4 for rejuvenating human cellsSG11201507334VA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361800668P	2013-03-15	2013-03-15
PCT/US2014/029537WO2014144932A2 (en)	2013-03-15	2014-03-14	Methods of using zscan4 for rejuvenating human cells

Publications (1)

Publication Number	Publication Date
SG11201507334VAtrue SG11201507334VA (en)	2015-10-29

Family

ID=51538396

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201507334VASG11201507334VA (en)	2013-03-15	2014-03-14	Methods of using zscan4 for rejuvenating human cells

Country Status (15)

Country	Link
US (6)	US10744183B2 (en)
EP (3)	EP4410976A3 (en)
JP (5)	JP2016518824A (en)
KR (3)	KR20230149853A (en)
CN (2)	CN105246490A (en)
AU (3)	AU2014233500B2 (en)
CA (4)	CA3176825A1 (en)
ES (2)	ES2987770T3 (en)
IL (2)	IL297168A (en)
MX (2)	MX376776B (en)
NZ (2)	NZ712334A (en)
RU (1)	RU2735141C2 (en)
SG (1)	SG11201507334VA (en)
WO (1)	WO2014144932A2 (en)
ZA (2)	ZA201506920B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2489081B (en)*	2010-03-16	2013-03-27	Organovo Inc	Multilayered vascular tubes
SG11201507334VA (en)	2013-03-15	2015-10-29	Elixirgen Llc	Methods of using zscan4 for rejuvenating human cells
US11530381B2 (en)	2016-07-20	2022-12-20	The Johns Hopkins University	Oxygen gradient hydrogel drug screening
US11136555B2 (en)	2017-03-01	2021-10-05	Elixirgen Scientific, Inc.	Compositions and methods for differentiation of human pluripotent stem cells into desired cell types
CN109420169B (en)*	2017-08-25	2021-07-20	中国科学院上海营养与健康研究所	Novel tumor-related target Zscan4 and its application in tumor suppression
CN108251455B (en)*	2018-02-02	2021-02-26	温州医科大学附属第二医院、温州医科大学附属育英儿童医院	Construction method and application of cervical squamous cell carcinoma CaSki cells with stable and low expression of RAGE
US20210079402A1 (en)*	2018-02-20	2021-03-18	University Of Maryland, Baltimore	Inhibition of zscan4 for inhibition of tumor growth
CN108342474A (en)*	2018-04-13	2018-07-31	东华大学	A kind of kit for detecting telomere length prediction coronary heart disease risk
US20220306730A1 (en)*	2019-05-22	2022-09-29	University Of Maryland, Baltimore	Methods of treating cancer by targeting zscan4 activity in cancer stem cells
MX2022007910A (en)*	2019-12-31	2022-08-25	Elixirgen Therapeutics Inc	Temperature-based transient delivery of zscan4 nucleic acids and proteins to cells and tissues.
WO2021138447A1 (en)	2019-12-31	2021-07-08	Elixirgen Therapeutics, Inc.	Temperature-based transient delivery of nucleic acids and proteins to cells and tissues
CN112375824B (en)*	2020-11-13	2022-07-05	山东大学齐鲁医院	Application of MSC as cervical cancer diagnosis, prognosis and/or treatment marker
US20250064775A1 (en)*	2022-01-04	2025-02-27	Trustees Of Tufts College	Selective elimination of senescent cells by ferroptosis induction
WO2023150285A1 (en)	2022-02-04	2023-08-10	Elixirgen Therapeutics, Inc.	Cell therapy protocol systems and methods
WO2025160341A1 (en)*	2024-01-24	2025-07-31	The Children's Medical Center Corporation	Manipulation of purine nucleotide metabolism as therapies

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4797368A (en)	1985-03-15	1989-01-10	The United States Of America As Represented By The Department Of Health And Human Services	Adeno-associated virus as eukaryotic expression vector
US4980289A (en)	1987-04-27	1990-12-25	Wisconsin Alumni Research Foundation	Promoter deficient retroviral vector
US5871472A (en)	1987-11-17	1999-02-16	Brown University Research Foundation	Planting devices for the focal release of neuroinhibitory compounds
US5888762A (en)	1990-06-05	1999-03-30	Centre National De La Recherche Scientifique (Cnrs)	Neurotropic growth factors comprising a homeobox peptide
US5489508A (en)*	1992-05-13	1996-02-06	University Of Texas System Board Of Regents	Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
KR100201352B1 (en)	1995-03-16	1999-06-15	성재갑	Single injection vaccine formulation
US5741677A (en)*	1995-06-07	1998-04-21	Geron Corporation	Methods for measuring telomere length
US7198784B2 (en)	1996-10-17	2007-04-03	Oxford Biomedica (Uk) Limited	Retroviral vectors
FR2762615B1 (en)	1997-04-28	1999-07-16	Inst Nat Sante Rech Med	NEW INTERNAL RIBOSOME ENTRY SITE AND VECTOR CONTAINING THE SAME
US6110902A (en)	1997-06-23	2000-08-29	Moehler; Hanns	Method for the inhibition of neuronal activity leading to a focal epileptic seizure by local delivery of adenosine
CN1364197A (en)	1999-06-22	2002-08-14	株式会社载体研究所	Vector for expressing two foreign genes
DE19933492B4 (en)	1999-07-16	2008-01-10	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Conjugate for the mediation of a cell-, compartment- or membrane-specific transport of active substances, process for its preparation and its use
JP2003508079A (en)*	1999-09-07	2003-03-04	アドバンスドセルテクノロジー、インコーポレイテッド	Telomere recovery and prolongation of cell lifespan in animals cloned from senescent somatic cells
EP1235914A2 (en)	1999-11-24	2002-09-04	Joseph Rosenecker	Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells
AU2002224113A1 (en)	2000-11-27	2002-06-03	Dnavec Research Inc.	Paramyxovirus vector encoding angiogenesis gene and utilization thereof
US7211247B2 (en)	2001-04-09	2007-05-01	University Of Southern California	Lentivirus vectors for gene transfer to alveolar epithelial cells
US7081489B2 (en)	2001-08-09	2006-07-25	Florida State University Research Foundation	Polymeric encapsulation of nanoparticles
EP2116604A1 (en)	2002-08-05	2009-11-11	University of Rochester	Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
KR100591936B1 (en)	2002-11-12	2006-06-22	포휴먼텍(주)	Intracellular DNA / RNA Delivery Methods, and Their Basic and Clinical Applications
EP1583473A2 (en)	2003-01-16	2005-10-12	St. Johns University New York	Nanoparticle based stabilization of ir fluorescent dyes
US7166692B2 (en)	2003-03-04	2007-01-23	Canbrex Bio Science Walkersville, Inc.	Intracellular delivery of small molecules, proteins, and nucleic acids
NZ549040A (en)*	2004-02-17	2009-07-31	Schering Corp	Use for interleukin-33 (IL33) and the IL-33 receptor complex
WO2006052285A2 (en)	2004-05-13	2006-05-18	The Trustees Of Columbia University In The City Of New York	Polymeric nanoparticles and nanogels for extraction and release of compounds
US20060024331A1 (en)	2004-08-02	2006-02-02	Ester Fernandez-Salas	Toxin compounds with enhanced membrane translocation characteristics
EP1716847B1 (en)	2005-04-28	2008-01-02	Nipro Corporation	Bioabsorbable pharmaceutical formulation comprising a PLGA copolymer
CN101189020A (en)	2005-05-10	2008-05-28	N·巴拉班	Compositions for administration of RNA III-inhibitory peptides
BRPI0612423A2 (en)*	2005-05-17	2009-01-27	Reliance Life Sciences Pvt Ltd	pedigree establishment of human embryonic stem cells using mammalian cells
US8278104B2 (en)	2005-12-13	2012-10-02	Kyoto University	Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
JP5705535B2 (en)	2007-03-26	2015-04-22	アメリカ合衆国	Methods for regulating embryonic stem cell differentiation
US8580281B2 (en)	2008-02-27	2013-11-12	Hisamitsu Pharmaceutical Co., Inc.	Medicated patch
JP2011519030A (en)*	2008-04-25	2011-06-30	ルドルフ、レンハルト	Markers for measuring DNA damage and telomere dysfunction to measure biological aging, regenerative potential, carcinogenic risk, risk of developing age-related diseases and prognosis of chronic diseases in humans and animals
JP5565790B2 (en)	2009-06-30	2014-08-06	日本モレックス株式会社	Edge connector
US8741649B2 (en)	2009-09-04	2014-06-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Methods for enhancing genome stability and telomere elongation in embryonic stem cells
JP6294079B2 (en)	2011-01-25	2018-03-14	ミノルシルホンコー	ZSCAN4 and its use as a marker for pancreatic stem cells and progenitor cells
US11059869B2 (en)	2011-03-23	2021-07-13	Elixirgen, Llc	Compositions for enhancing the pluripotency of stem cells
WO2012158564A1 (en)	2011-05-13	2012-11-22	The United States Of America As Represented By The Secretary, Department Of Health & Human Services	Compositions and methods for increasing the frequency of homologous recombination
US9932560B2 (en)	2011-05-13	2018-04-03	Elixirgen, Llc	Use of Zscan4 and Zscan4-dependent genes for direct reprogramming of somatic cells
SG11201507334VA (en)	2013-03-15	2015-10-29	Elixirgen Llc	Methods of using zscan4 for rejuvenating human cells

2014
- 2014-03-14SGSG11201507334VApatent/SG11201507334VA/enunknown
- 2014-03-14JPJP2016503126Apatent/JP2016518824A/enactivePending
- 2014-03-14USUS14/211,638patent/US10744183B2/enactiveActive
- 2014-03-14CACA3176825Apatent/CA3176825A1/enactivePending
- 2014-03-14RURU2015144049Apatent/RU2735141C2/enactive
- 2014-03-14CNCN201480027460.1Apatent/CN105246490A/enactivePending
- 2014-03-14WOPCT/US2014/029537patent/WO2014144932A2/ennot_activeApplication Discontinuation
- 2014-03-14MXMX2015012176Apatent/MX376776B/enactiveIP Right Grant
- 2014-03-14KRKR1020237034818Apatent/KR20230149853A/ennot_activeCeased
- 2014-03-14CACA3176707Apatent/CA3176707A1/enactivePending
- 2014-03-14ESES20186939Tpatent/ES2987770T3/enactiveActive
- 2014-03-14ESES14762788Tpatent/ES2827248T3/enactiveActive
- 2014-03-14EPEP24167285.6Apatent/EP4410976A3/enactivePending
- 2014-03-14CACA2906213Apatent/CA2906213C/enactiveActive
- 2014-03-14KRKR1020227001388Apatent/KR20220011805A/ennot_activeCeased
- 2014-03-14NZNZ712334Apatent/NZ712334A/enactiveIP Right Revival
- 2014-03-14EPEP20186939.3Apatent/EP3782628B1/enactiveActive
- 2014-03-14CACA3176712Apatent/CA3176712A1/enactivePending
- 2014-03-14CNCN202010576857.3Apatent/CN111979198A/enactivePending
- 2014-03-14ILIL297168Apatent/IL297168A/enunknown
- 2014-03-14KRKR1020157028431Apatent/KR102352848B1/enactiveActive
- 2014-03-14EPEP14762788.9Apatent/EP2968392B1/enactiveActive
- 2014-03-14AUAU2014233500Apatent/AU2014233500B2/enactiveActive
- 2014-03-14USUS14/776,707patent/US10335456B2/enactiveActive
- 2014-03-14NZNZ751639Apatent/NZ751639A/enunknown
2015
- 2015-09-10ILIL241539Apatent/IL241539B2/enunknown
- 2015-09-10MXMX2020011415Apatent/MX2020011415A/enunknown
- 2015-09-17ZAZA2015/06920Apatent/ZA201506920B/enunknown
2019
- 2019-03-27JPJP2019061654Apatent/JP6889747B2/enactiveActive
- 2019-05-30USUS16/427,097patent/US20190282660A1/ennot_activeAbandoned
- 2019-05-30USUS16/427,038patent/US11389504B2/enactiveActive
- 2019-09-13AUAU2019229444Apatent/AU2019229444B2/enactiveActive
2020
- 2020-10-16ZAZA2020/06429Apatent/ZA202006429B/enunknown
2021
- 2021-05-21JPJP2021085867Apatent/JP7331040B2/enactiveActive
- 2021-12-15AUAU2021286335Apatent/AU2021286335A1/ennot_activeAbandoned
2022
- 2022-06-30USUS17/855,584patent/US20220331399A1/enactivePending
2023
- 2023-01-13USUS18/154,742patent/US20230226148A1/enactivePending
- 2023-05-26JPJP2023087016Apatent/JP7633309B2/enactiveActive
2025
- 2025-02-06JPJP2025018200Apatent/JP2025065335A/enactivePending

Also Published As

Publication number	Publication date
RU2020133279A3 (en)	2022-04-29
CN111979198A (en)	2020-11-24
CN105246490A (en)	2016-01-13
BR112015023603A2 (en)	2017-10-24
AU2019229444A1 (en)	2019-10-03
MX2020011415A (en)	2020-11-24
JP7331040B2 (en)	2023-08-22
US20140322176A1 (en)	2014-10-30
US11389504B2 (en)	2022-07-19
KR20150134360A (en)	2015-12-01
EP3782628A1 (en)	2021-02-24
US20190282659A1 (en)	2019-09-19
IL241539A (en)	2015-11-30
EP2968392A2 (en)	2016-01-20
NZ712334A (en)	2021-07-30
IL297168A (en)	2022-12-01
EP3782628C0 (en)	2024-08-07
EP2968392A4 (en)	2016-08-03
MX376776B (en)	2025-03-07
ZA202006429B (en)	2022-01-26
US10335456B2 (en)	2019-07-02
JP2021118752A (en)	2021-08-12
AU2014233500A1 (en)	2015-10-08
EP4410976A2 (en)	2024-08-07
IL241539B (en)	2022-11-01
US20160030514A1 (en)	2016-02-04
JP7633309B2 (en)	2025-02-19
ES2827248T3 (en)	2021-05-20
EP3782628B1 (en)	2024-08-07
US20190282660A1 (en)	2019-09-19
WO2014144932A2 (en)	2014-09-18
US20220331399A1 (en)	2022-10-20
KR102352848B1 (en)	2022-01-19
RU2015144049A (en)	2017-04-21
MX2015012176A (en)	2016-04-25
AU2021286335A1 (en)	2022-01-20
US10744183B2 (en)	2020-08-18
KR20220011805A (en)	2022-01-28
JP2016518824A (en)	2016-06-30
CA3176825A1 (en)	2014-09-18
JP2019122398A (en)	2019-07-25
EP2968392B1 (en)	2020-08-05
EP4410976A3 (en)	2025-02-12
CA2906213C (en)	2023-09-26
JP2025065335A (en)	2025-04-17
AU2019229444B2 (en)	2021-12-02
CA3176712A1 (en)	2014-09-18
ZA201506920B (en)	2021-01-27
RU2015144049A3 (en)	2018-03-29
RU2020133279A (en)	2020-11-11
US20230226148A1 (en)	2023-07-20
CA2906213A1 (en)	2014-09-18
ES2987770T3 (en)	2024-11-18
IL241539B2 (en)	2023-03-01
JP6889747B2 (en)	2021-06-18
WO2014144932A3 (en)	2014-12-11
RU2735141C2 (en)	2020-10-28
CA3176707A1 (en)	2014-09-18
JP2023099826A (en)	2023-07-13
AU2014233500B2 (en)	2019-06-13
KR20230149853A (en)	2023-10-27
NZ751639A (en)	2021-07-30

Publication	Publication Date	Title
ZA202006429B (en)	2022-01-26	Methods of using zscan4 for rejuvenating human cells
IL241627B (en)	2020-05-31	Method for activating t cells
IL244791A0 (en)	2016-04-21	Methods of host cell modification
GB2546213B (en)	2017-12-06	Method of isolating circulating tumour cells
EP2971040A4 (en)	2016-08-17	Methods of cell culture
GB2510821B (en)	2015-08-19	Charging Method
EP2971014A4 (en)	2016-08-17	Methods of cell culture
SG11201705401YA (en)	2017-08-30	Methods to improve cell therapy
PL2988659T3 (en)	2023-01-02	Improved methods of tissue characterization
IL245392A0 (en)	2016-06-30	Cell culture method
PL3071969T3 (en)	2018-09-28	Method of analysis
GB2525562B (en)	2017-10-11	Methods for purification of biological cells
EP3024081A4 (en)	2016-07-27	Method for producing cell
IL245272A0 (en)	2016-06-30	Pif-transfected cells and methods of use
SG11201602266YA (en)	2016-04-28	Method of extracting protein
PL2984208T3 (en)	2017-07-31	Method of retrofitting of finite-gap electrolytic cells
IL241096B (en)	2021-05-31	Method of treatment
GB2518928B (en)	2017-03-01	Method of depilation
GB201306810D0 (en)	2013-05-29	Methods of cell separation
GB201303474D0 (en)	2013-04-10	Cells and method for fatty acid synthesis
SG11201507338PA (en)	2015-10-29	Method for culturing cells
IL241475A0 (en)	2015-11-30	Method of synthesis
GB201315033D0 (en)	2013-10-02	Method of cell preservation
GB201322778D0 (en)	2014-02-05	Method of treatment
GB201314882D0 (en)	2013-10-02	Method of treatment

Movatterモバイル変換

SG11201507334VA - Methods of using zscan4 for rejuvenating human cells - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=51538396

Family Applications (1)

Country Status (15)

Families Citing this family (15)

Family Cites Families (38)

Also Published As

Similar Documents